E78

Disorders of lipoprotein metabolism and other lipidemias

Disorders of lipoprotein metabolism and other lipidemias, classified under ICD-10 code E78, represent a broad category encompassing various conditions characterized by abnormal levels of lipids (fats) in the blood, primarily cholesterol and triglycerides, or abnormalities in the lipoproteins responsible for transporting these lipids. This diagnostic category is crucial for identifying patients at increased risk for cardiovascular diseases, pancreatitis, and other systemic complications. The E78 category serves as a non-billable parent code, necessitating further specificity through its sub-codes (E78.0-E78.9) for accurate clinical documentation and billing purposes.These disorders can be broadly divided into primary (genetic) and secondary (acquired) forms. Primary dyslipidemias often result from inherited genetic mutations affecting lipoprotein synthesis, catabolism, or receptor function, leading to conditions like familial hypercholesterolemia or familial combined hyperlipidemia. Secondary dyslipidemias are more common and are typically associated with lifestyle factors (e.g., diet, lack of exercise), underlying medical conditions (e.g., diabetes mellitus, hypothyroidism, chronic kidney disease, obstructive liver disease), or medications (e.g., corticosteroids, thiazide diuretics).Accurate classification within the E78 category is vital for guiding therapeutic interventions, which may include lifestyle modifications, pharmacotherapy (e.g., statins, fibrates, PCSK9 inhibitors), or in some severe cases, apheresis. The specific sub-codes within E78 allow clinicians to precisely characterize the lipid abnormality, such as pure hypercholesterolemia (E78.0), pure hypertriglyceridemia (E78.1), or mixed hyperlipidemia (E78.2), which in turn dictates the most appropriate management strategy. Unspecified codes like E78.5 (Hyperlipidemia, unspecified) should be used judiciously, ideally when specific lipid profiles are not yet determined or if the exact type of dyslipidemia cannot be classified more precisely after thorough investigation.

Clinical Symptoms

  • Lipid disorders often present asymptomatically, being detected through routine blood tests.
  • When symptoms do occur, they are generally related to complications rather than the elevated lipids themselves.
  • Xanthomas (fatty deposits under the skin, especially around the eyes or on tendons)
  • Xanthelasma (yellowish patches on eyelids)
  • Arcus corneae (a white, grey, or blue ring in the corneal margin, especially in younger individuals)
  • Abdominal pain (in severe hypertriglyceridemia, indicating pancreatitis)
  • Symptoms of cardiovascular disease (e.g., angina, shortness of breath, claudication)
  • Symptoms of peripheral artery disease
  • Neurological symptoms in rare cases of severe genetic disorders affecting lipid metabolism

Common Causes

  • Genetic Factors (Primary Dyslipidemias): Inherited conditions affecting lipid synthesis, transport, or catabolism, such as familial hypercholesterolemia, familial hypertriglyceridemia, or familial combined hyperlipidemia.
  • Dietary Factors: High intake of saturated fats, trans fats, and cholesterol.
  • Lack of Physical Activity: Sedentary lifestyle contributing to metabolic imbalances.
  • Obesity: A significant risk factor for dyslipidemia.
  • Diabetes Mellitus: Poorly controlled diabetes often leads to dyslipidemia.
  • Hypothyroidism: Underactive thyroid gland can cause elevated cholesterol levels.
  • Chronic Kidney Disease: Impaired renal function can disrupt lipid metabolism.
  • Liver Diseases: Conditions like cholestasis or primary biliary cirrhosis can affect lipid profiles.
  • Medications: Certain drugs, including corticosteroids, thiazide diuretics, beta-blockers, and some antiretroviral therapies, can induce dyslipidemia.
  • Alcohol Consumption: Excessive alcohol intake can raise triglyceride levels.
  • Smoking: Contributes to endothelial dysfunction and exacerbates dyslipidemia.

Documentation & Coding Tips

Always specify the exact type of lipoprotein disorder (e.g., pure hypercholesterolemia, pure hypertriglyceridemia, mixed hyperlipidemia) and its underlying cause if known (e.g., familial, acquired).

Example: SUBJECTIVE: Patient is a 58-year-old male with a history of long-standing, uncontrolled mixed hyperlipidemia (E78.2) despite maximal statin therapy. Reports occasional chest tightness with exertion.OBJ: BP 140/90, HR 72. LDL 180 mg/dL, HDL 35 mg/dL, Triglycerides 250 mg/dL.ASSESSMENT: 1. Mixed hyperlipidemia, uncontrolled (E78.2), chronic, severe. Patient is at high risk for cardiovascular events. 2. Angina, stable (I20.9), likely exacerbated by dyslipidemia and underlying atherosclerotic disease.PLAN: Continue atorvastatin 80mg daily. Discussed adding ezetimibe to further reduce LDL. Ordered stress test. Patient counseled on low-fat diet and exercise. Discussed risk of ASCVD. Patient understands chronic nature of his condition. Follow up in 3 months. (Note supports chronic condition management, high severity, and potential complications for HCC/RAF calculation. Specificity of E78.2 instead of just E78.5 allows for better billing accuracy.)

Billing Focus: Specificity of the lipid disorder type (E78.0-E78.8 codes). Documentation of 'uncontrolled' or 'familial' indicates higher complexity. Linking to 'chronic' status and specific complications.

Document the control status and management plan, including patient adherence, response to treatment, and any complications arising from the dyslipidemia.

Example: SUBJECTIVE: 62-year-old female, known familial hypercholesterolemia (E78.0), on rosuvastatin 20mg daily for 5 years. Reports good medication adherence but recent lipid panel shows persistently elevated LDL. Denies chest pain or other new cardiac symptoms.OBJ: BP 128/80, HR 68. Recent labs: LDL 135 mg/dL (goal <100), HDL 50 mg/dL, Triglycerides 110 mg/dL.ASSESSMENT: 1. Familial hypercholesterolemia, poorly controlled (E78.0). Discussed patient's inability to achieve target LDL despite maximal statin therapy. This chronic condition significantly increases her risk for future cardiovascular events. 2. History of Type 2 Diabetes Mellitus (E11.9) with good glycemic control, managed with metformin.PLAN: Initiated PCSK9 inhibitor, evolocumab 140mg SC Q2W. Provided patient education on injection technique. Will recheck lipid panel in 6 weeks. Encouraged continued adherence to diet and exercise. Follow-up in 2 months. (This note highlights a chronic, poorly controlled genetic condition (E78.0) requiring advanced therapy, supporting higher E/M level and HCC for familial hypercholesterolemia. It also shows a comprehensive management plan.)

Billing Focus: Documentation of 'familial' (E78.0), 'poorly controlled,' or 'uncontrolled' justifies higher complexity E/M services. The initiation of advanced therapies (e.g., PCSK9 inhibitors) also supports medical necessity and higher E/M levels. Explicitly state the patient's adherence and response.

Clearly link dyslipidemia to any associated complications, such as atherosclerosis, coronary artery disease, or pancreatitis, specifying laterality and severity where applicable.

Example: SUBJECTIVE: 70-year-old male with long-standing hypertriglyceridemia (E78.1) presents with severe epigastric pain radiating to the back for 2 days. Reports recent dietary indiscretion. His triglycerides have been poorly controlled for months despite fibrate therapy.OBJ: T 37.8°C, HR 105, BP 130/85. Abdomen tender in epigastric region. Labs: Lipase 800 U/L, Triglycerides 1200 mg/dL. CT Abdomen shows pancreatic edema and inflammation consistent with acute pancreatitis.ASSESSMENT: 1. Acute pancreatitis due to severe hypertriglyceridemia (K85.80, E78.1). This represents a severe, acute complication directly linked to his chronic, uncontrolled lipid disorder. 2. History of Type 2 Diabetes Mellitus (E11.9) with peripheral neuropathy (E11.40).PLAN: Admit to hospital. NPO. IV fluids. Pain control. Initiate insulin drip for hypertriglyceridemia management. Consult GI. Monitor for complications. Will review fibrate therapy upon discharge. (This example directly links the acute condition (pancreatitis, K85.80) to the underlying chronic dyslipidemia (E78.1), demonstrating causality and severity. This robust documentation supports both diagnoses and the medical necessity for hospitalization.)

Billing Focus: Explicitly linking the acute complication (K85.80 acute pancreatitis) to the underlying chronic condition (E78.1 severe hypertriglyceridemia) enhances medical necessity for services and supports accurate coding of both conditions. This also helps in demonstrating the severity of the primary diagnosis.

Relevant CPT Codes

Related Diagnoses

Hierarchy